Celcuity is a clinical-stage biotechnology company developing molecularly targeted therapies for solid tumor cancers driven by PI3K pathway dysregulation. Its lead candidate, gedatolisib, is a pan-PI3K/mTOR inhibitor being evaluated in Phase 3 trials for HR+/HER2- advanced breast cancer and has received an FDA NDA acceptance. The company also develops companion diagnostics to identify patients most likely to benefit from its precision oncology therapies.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account